Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Chemotherapy With or Without Monoclonal Antibody in Treating Women With Metastatic Breast Cancer

Study:

A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating The Efficacy, Safety, And Pharmacokinetics Of rhuMAb VEGF (BEVACIZUMAB), In Combination With Capecitabine Chemotherapy, In Subjects With Previously Treated Metastatic Breast Cancer

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if chemotherapy is more effective with or without monoclonal antibody in treating metastatic breast cancer.

Purpose:

Randomized phase III trial to study the effectiveness of capecitabine with or without bevacizumab in treating women who have metastatic breast cancer.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Breast Cancer Drug: bevacizumab
Drug: capecitabine
Phase 3

Verified by Genentech September, 2005

Sponsored by: Genentech
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00012285

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Amy Vassel, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site